All In Biotech

Drug Trial Radar · NCT05466890

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Sep 15, 2022

Primary completion

Feb 10, 2025

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Palatin Technologies, IncIndustry
Sponsor type
Industry
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).

Conditions

  • Ulcerative Colitis
  • Ulcerative Colitis Acute
  • Ulcerative
  • Ulcerative Colitis Flare

Interventions

  • PL8177 PlaceboDrug

    Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.

  • PL8177Drug

    Approximately 3/4 of randomized patients will receive active PL8177.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of PL8177 compared to placebo in patients with active UC.Time frame: Baseline through Study Completion (Week 12).
  2. To compare the proportion of subjects achieving Mayo Endoscopic Subscore of ≤ 1 point (0 or 1) between PL8177 and placebo after 8 weeks of treatment.Time frame: Time Frame: Mayo Endoscopic Subscore will be evaluated at Week 8.

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • Gastro Care Institute

    Lancaster, California

  • Valiance Clinical Research

    Tarzana, California

  • Advanced Research LLC

    Coral Springs, Florida

  • IHS Health Research/Gastro Health

    Kissimmee, Florida

  • Orlando Health, Inc.

    Orlando, Florida

  • Kansas Gastroenterology

    Wichita, Kansas

  • Gastroenterology Clinic of Acadiana

    Lafayette, Louisiana

  • Delta Research Partners

    Monroe, Louisiana

  • Allied Health Clinical Research Organization, LLC - Englewood

    Englewood, New Jersey

  • Allied Digestive Health LLC

    Freehold, New Jersey

  • Allied Health Clinical Research Organization, LLC

    Jackson, New Jersey

  • Weill Cornell Medicine - Jill Roberts Center for Inflammatory Bowel Disease

    New York, New York

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.